It is often challenging for the clinician interested in cystic fibrosis (CF) to interpret molecular genetic results, and to integrate them in the diagnostic process. The limitations of genotyping technology, the choice of mutations to be tested, and the clinical context in which the test is administered can all influence how genetic information is interpreted. This paper describes the conclusions of a consensus conference to address the use and interpretation of CF mutation analysis in clinical settings.
A huge amount of information has been published on the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene since it was identified in 1989 [1] [2] [3] . Remarkable developments in molecular analysis techniques have resulted in the identification of more than 1500 CFTR mutations [4] , and high sensitivity mutation panels are now available for many populations or ethnic groups. The great strides in molecular genetics need to be matched by equal progress in clinical interpretation and communication. The meaning of rare mutations in the diagnostic field, genotype/phenotype correlation in the single individual, and the clinical relevance of complex alleles and modifier genes are all issues which often raise more questions than answers. It is often challenging for the clinician interested in CF to interpret the molecular results, and to integrate them in the diagnostic process.
A Consensus Conference organized by the European Cystic Fibrosis Society (www.ecfsoc.org), with the partnership of the European Society of Human Genetics (www.eshg,org), and the EuroGentest Network of Excellence (www.eurogentest.org), took place in Garda, Italy, on March 23-24, 2007 . Its main purpose was to provide the CF clinician with information relevant for the best use of CF genetic testing. Thirty experts in cystic fibrosis and molecular genetics from Europe and North America were involved in pre-conference consultations and in 193 196 the drafting of preliminary documents, and twenty-three attended the meeting. The conference addressed a wide range of issues, including CFTR analysis technical standards, distribution of mutations, complex alleles, the use of genetic testing for the diagnosis of cystic fibrosis, genotype/phenotype correlation including potential impact of modifier genes, and proper communication of the genetic test result. This document is the result of the Consensus Conference.
Mutations in the CFTR gene and their analysis

Distribution of mutations
Cystic fibrosis is caused by mutations in the CFTR (ABCC7) gene [1] [2] [3] . The most common mutation is F508del, previously termed ΔF508, which accounts for approximately two thirds of all CFTR alleles in patients with CF, with a decreasing prevalence from Northwest to Southeast Europe [5] [6] [7] [8] [9] [10] . The remaining third of alleles are substantially heterogeneous, with fewer than 20 mutations occurring at a worldwide frequency of more than 0.1% [4, 11] . Some mutations can reach a higher frequency in certain populations, due to a founder effect in religious, ethnic or geographical isolates [12, 13] (Tables 1 and 2 ).
The majority of CFTR mutations have been associated with European-derived populations [6] . There are also CFTR mutations in non-European populations, such as African and East Asian populations [14] , but no alleles have reached the high frequency of F508del.
Overviews of the distribution of CFTR mutations causing CF have been produced by WHO [11] and Bobadilla et al. [15] . In approximately two thirds of all instances the entire CFTR coding region has been analysed, and therefore in these reports some mutations which were easier to screen for are over-represented, compared to those which are more difficult to determine from the technical point of view. The reviews do not contain data on intra-CFTR rearrangements, and have limited information on mutations occurring in non-European-derived populations. A project for updating the previous WHO review is currently in progress.
To date more than 1500 sequence alterations have been identified in the CFTR gene and their listing is continuously updated within the Cystic Fibrosis Genetic Analysis Consortium (CFGAC) database [4] . In the database missense mutations account for 42%, frameshift for 15%, splicing for 12%, nonsense for around 10%, inframe insertions/deletions for 2%, large insertions/deletions for 3%, promoter mutations for 0.5%, and sequence variations which are not predicted to be disease-causing for 15% of all alleles. De novo mutations and uniparental disomy of chromosome 7 bearing a mutated CFTR gene are exceptional events.
Conclusion: CFTR mutations vary in their frequency and distribution in different populations. Very few mutations have a worldwide frequency above 0.1%, but some can reach high prevalence in selected populations. 
Methods in genetic testing
CFTR genetic analysis panels should have a mutation detection rate superior to 95%, but the heterogeneity of CFTR mutations in various populations makes this goal extremely challenging using the current molecular genetic techniques. Every effort should be made to determine the frequency of specific CF mutations within the target population and to provide testing with reasonably high sensitivity levels. Laboratories that service a particular ethnic population should consider including ethnic-specific mutations into their panel [16] . Different testing panels might be employed for identification of CFTR mutations in patients diagnosed with CF, as opposed to relatives of CF patients, where the family specific mutation should be tested first. An extended mutation panel may be appropriate for certain diagnostic testing purposes, but it is not currently recommended for routine carrier screening [17] .
Evidence has accumulated that a group of intragenic rearrangements (i.e. large deletions and to lesser a extent insertions) [18] account for about 1-3% of all CFTR mutations. The large deletions and/or insertions so far detected are mainly localised around CFTR exons 2-3 and 17b. These deletions are rare, with the exception of CFTRdele2,3 (21kb), which accounts for 6% of all CF alleles in Slavic populations [19] . These alleles are optimally examined either by Multiplex Ligation-dependent Probe Amplification (MLPA) or Quantitative Fluorescent Multiplex PCR [20, 21] .
Mutation scanning approaches (DGGE, DHPLC, HRMCA) have been designed to explore the gene exon by exon for abnormalities, most often as a second-step analysis after screening for frequent mutations. Sequencing is then used to characterize the abnormal pattern. Scanning techniques are still widely used although it has become feasible to sequence the entire CFTR gene in the diagnostic setting [22] . However, mutation scanning techniques result in a considerable risk of missing mutations, in particular homozygous alleles, and even with complete gene sequencing a small risk remains. Sequencing is also used when the mutation under investigation cannot be detected by alternative direct techniques, e.g. after the population specific panel has been exhausted and/or mutations that occur at a frequency of at least 0.5% have been excluded. Once a rare missense mutation has been identified, caution has to be exercised in order not to over interpret its significance to disease causation.
The combined use of all these techniques cannot guarantee to detect both mutated alleles in all patients with CF [18, [23] [24] [25] , 1-5% of CF alleles remaining undetermined. Currently used CFTR mutation analysis protocols are not capable of identifying CFTR regulatory mutations located in sites distant from the gene or embedded in the genes' non-coding regions [26] . At present, research is ongoing to identify eventual mutations in potential regulatory elements, including the gene promoter [27] , highly conserved DNA segments, DNAse hypersensitive sites, and/or distant regulatory elements [28] . Mutations of this type are expected to abolish or reduce production of functional CFTR [29] , and could be associated with a clinical spectrum from classic CF to CFTR-related disorders. In a small number of CF families, in which only one or no CFTR mutations have been identified, segregation analysis of CFTR polymorphic non pathogenic markers may provide further helpful information for identifying disease genes. Multiple informative markers are available both in the CFTR gene and flanking the gene. It is recommended that more than one marker be included in the analysis, and the diagnosis of CF in the index case should be clearly defined. Ideally, one should use intragenic and extragenic markers, since the risk for unidentified recombination between marker and mutation is lower if flanking markers are concordant. Analysis of variable markers at loci on different chromosomes should also be performed when offering prenatal diagnosis as an added safeguard for maternal contamination.
Conclusion: Current analytic methods to detect mutations in the CFTR gene range from panels containing the most common disease-causing alleles to extensive scanning/sequencing protocols that enable the detection of novel mutations and to methods to identify large rearrangements. However, even the most extensive CFTR mutation screening tests fail to detect all CF alleles in most CF populations.
Quality control
DNA-based analyses are carried out in a variety of settings, including academic research laboratories, clinical molecular genetics laboratories, and private laboratories. As commercial kits are only available for limited number of mutations and are expensive, many laboratories, especially in less developed countries, use their own in-house test methodologies, which are usually not amenable to automation and rigorous standardization. These approaches have a higher risk of producing invalid results.
In Southern European populations, which show high molecular heterogeneity, commercial mutation panels cover only 50-75% of alleles and scanning/sequencing techniques may be used in genetic analysis performed for CF diagnostic purposes [8, 30] .
The diagnostic services should be organized at two levels: Level 1 (i.e. "local testing") where only frequent mutations are tested, ideally reaching 75-85% detection rate of CF-causing alleles in patients with a clearly defined phenotype, and Level 2, represented by a limited number of national and/or regional expert laboratories that test for less frequent mutations using more sophisticated technologies in order to achieve the highest possible mutation detection rate [31] [32] [33] . Each laboratory must show that its tests can consistently deliver the correct genotype under normal working conditions. In order to evaluate the quality of genetic testing for cystic fibrosis, a Cystic Fibrosis External Quality Assessment (EQA) scheme has been set up [34] . EQA schemes seek to educate participants, so that they can achieve high quality standards, and regular participation in EQA is a vital part of the quality assurance process and a requirement for laboratory accreditation. Different sources of errors include administration errors, technical errors or misinterpretation of technically correct results. The use of a commercial kit alone does not ensure high accuracy of mutation analysis, which stresses the importance of validating all genetic tests in the laboratory, and the need for laboratory networks at regional or national levels.
Clinicians should be aware that the quality of the test is associated with diagnostic validation procedures and continuous improvement of laboratory quality using the latest ISO norms or National Molecular Genetic Agreements. The minimal standard for countries without a national agreement system is "certification" (e.g. ISO 9001), while optimally the laboratory should be accredited according to ISO 17025 or 15189, which assures sustained and continuous improvement of the standards of laboratory testing. The EuroGentest FP6 Network of Excellence (www.eurogentest.org), together with Orphanet (www. orpha.net), is launching a Quality Assurance database where the referring clinicians will be able to select a laboratory that is accredited or certified.
Recommendation: Referring clinicians should use molecular genetic diagnostic services from certified and/or accredited laboratories.
The role of genetic analysis for establishing the diagnosis of CF
The diagnosis of CF is based on a consistent phenotype plus evidence of CFTR channel dysfunction (abnormal sweat chloride concentration or nasal potential difference), or identification of two CF-disease causing mutation in trans [35] . The sweat test with chloride determination is still the gold standard for confirming a CF diagnosis [35, 36] . In the majority of cases the diagnosis of CF is clear and easily made: the clinical features are typical, and the abnormal sweat chloride values support the clinical diagnosis. In such situations, genetic analysis is not strictly necessary, although it may be useful to confirm the diagnosis, and to enable carrier testing and prenatal diagnosis within the family. In a smaller fraction of patients, particularly those that carry one or more mutations that confer exocrine pancreatic sufficiency, sweat chloride concentrations may be within the reference range for unaffected controls. In some of these patients, provided they have consistent clinical features, genetic analysis may support a diagnosis of CF [35] [36] [37] .
From a formal genetic perspective, the term "mutation" is defined as a molecular alteration in the DNA sequence of a gene. Accordingly, this definition makes no assumptions concerning the potential effect of a mutation on the expression or function of the protein product. Thus, in terms of clinical consequences mutations can be neutral, deleterious or even beneficial. Another much used term, polymorphism, is defined as a DNA sequence alteration which has a frequency of at least 1% in the general population. Given their high frequency, polymorphisms were previously thought to have no clinical consequences. This assumption is clearly incorrect. Several polymorphisms in CFTR are known to influence disease severity in subjects with CF and CFTR-related disorders [38, 39] . Furthermore, polymorphisms in other genes, termed modifier genes, clearly contribute to the severity of CF disease.
CFTR mutations may be clustered into four groups according to their predicted clinical consequences: There is some overlapping of groups A and B, as some mutations may sometimes be detected in association with pancreatic sufficient CF, some other times with CFTR-related, mono-symptomatic disorders. Individuals carrying mutations like D1152H together with a CF-causing mutation like F508del may show a clinical spectrum ranging from CBAVD to CF with sufficient pancreatic function but fully expressed lung disease. Factors such as the age related progression of the disease, the environment, and modifier genes, all play a role in the clinical heterogeneity of patients carrying these "borderline" mutations. 
Mutations that cause CF
Ex vivo functional evaluation of the CFTR protein can help to predict the disease-causing implications of a sequence variation. In vivo assessment of CFTR-mediated chloride transport can be indirectly assessed by sweat chloride concentrations, nasal potential difference or rectal biopsy measurement of chloride transport.
Empiric evidence for the most common mutations and/or a clear pathogenic molecular mechanism for insertions, deletions, and nonsense mutations, strongly indicate that such mutations belong to the CF-causing group.
Splicing mutations that completely abolish exon recognition (such as 621 + 1G N T, 711 + 1 G N T and 1525-1G N A) give complete absence of correctly spliced transcripts, and thus belong to the CF-causing group [40, 41] . Splicing mutations that still result in a fraction of correctly spliced transcripts, together with aberrantly spliced transcripts, may belong to the CF-causing or CFTR-related disorders associated group (e.g. 3849 + 10kbC N T, 2789 + 5G N A, 3272-26A N G, IVS8-T5) [42] [43] [44] . Patients carrying these mutations often have a relatively mild phenotype, yet with variable disease expression, from minimal lung disease, pancreatic sufficiency and male fertility to a relative severe disease in all the involved organs [45, 46] . This Table 3 Examples of CFTR mutations with regard to their clinical consequences
Mutation group Examples
A. CF-causing F508del, R553X, R1162X, R1158X, 2184delA, 2184insA, 3120 + 1G N A, I507del, 1677delTA, G542X, G551D, W1282X, N1303K, 621 + 1G N T, 1717-1G N A, A455E, R560T, G85E, R334W, R347P, 711
Mainly missense mutations ⁎⁎⁎ ( ⁎ ) mutations which may belong either to Group A or to Group B.
( ⁎⁎ ) mutations which may belong either to Group B or to Group C.
( ⁎⁎⁎ ) certain common sequence (missense) variants with subclinical molecular consequences (e.g. M470V) may co-segregate on the same chromosome and exert more potent, cumulative phenotypic effect. Such polyvariant haplotypes could be potentially disease causing [56] . Only a fraction of mutation and patients have been characterized in detail, and, with the exception of frequent mutations, only limited sample numbers have been available for the study of most mutations. Data shown here have to be interpreted with caution. variable disease expression is inversely correlated with the quantity of correctly spliced transcripts, i.e. lower levels are associated with a severe disease, while higher levels are associated with a milder phenotype ( Table 4) . The quantity of correctly spliced transcripts may also differ among various organs of the same patient, contributing to differential organ disease severity [28, [47] [48] [49] [50] [51] [52] . Several groups studied the IVS8-T5 allele in the respiratory epithelium and epidydimis [49, 50] , showing that in CBAVD males the level of correctly spliced transcripts is lower in the epidydimis than in the respiratory epithelium (10-24% versus 26-37%), whereas in an infertile male CF patient with a severe lung disease the level of correctly spliced transcripts was low in both tissues. A similar correlation was also shown for the 3849 + 10kbC N T mutation [51] .
The extent of abnormal splicing in a patient is not determined in routine diagnostics tests, because cells expressing CFTR are difficult to obtain in sufficient quantities, and their analysis is very laborious. Besides, the percentage of correctly spliced transcripts in patients with mild disease varies within a large range of 4% to 50%, whereas severe disease is caused by lower levels of correct transcripts.
The clinical role of missense mutations is extremely difficult to assess. The identification of a missense mutation in a single family/individual makes it impossible to determine with certainty whether it has any consequential effect. Several missense mutations are commonly seen in the general population but also, more frequently, in patients with CFTR-associated disorders. For a small fraction of mutations, the functional consequences have been determined in research projects, and these findings can be used to predict the most likely consequences of such a mutation.
These difficulties account for the lack of a clearly established or substantiated knowledge of the pathogenic potential of the majority of the known CFTR mutations. However, a general acknowledgement [36] has been agreed upon that a sequence variation may be predicted to cause CF if:
-it causes a change in the amino acid sequence that severely affects CFTR synthesis and/or function -it introduces a premature termination signal (insertion, deletion or nonsense mutation) -it alters the invariant nucleotide of intron splice sites.
Other criteria can be used to asses the pathogenic potential, but they provide a lower degree of certainty. Some of them include:
-the sequence variation causes a novel amino acid sequence that does not occur in the normal CFTR gene from at least 100 carriers of CF mutations from the patients ethnic group -the sequence variation is detected in a set number of unrelated individuals with CF -the sequence variant changes a highly evolutionarily conserved amino acid residue -the sequence variation creates a novel/cryptic splice site -similar sequence variations are found in other ABC genes.
Indirect evidence that a CFTR sequence variations does not cause CF is:
-the other allele is carrying a well know CF-causing mutation in a clearly asymptomatic individual -a silent exonic sequence variation, without a priori splicing modification -an intronic sequence variation outside the known consensus sites and which does not create a splicing site -frequency in the general population equal to or above 0.4% [53] .
Conclusion: Mutation analysis is not the answer to every diagnostic dilemma: its limitations and role must be understood by the clinician, who has to interpret and use it in the context of the clinical setting. The majority of the CFTR mutations have not been functionally characterized, and for most the pathogenic potential is not clear.
Complex alleles
Genetic analysis may result in the identification of a common CF-causing mutation and a rare CFTR mutation or of two CFTR mutations. Under these circumstances, segregation analysis should be performed in the family of the patient. If the two mutations are on the same parental CFTR gene, it is said they are in cis; if each mutation is on a different parental CFTR gene, it is said they are in trans. When the two mutations are in cis, CF may not be confirmed, and the search of another allelic mutation, located in trans of the other two, should be continued. CFTR genes that carry at least two functional DNA alterations in cis, are called "complex alleles". The best understood complex alleles of the CFTR gene are the associations of intron 8 (IVS-8) variants TG13-T5, TG12-T5 and TG11-T5, of R117H-T5 and R117H-T7, and of mutations I148T and 3199del6.
A. TG13-T5, TG12-T5 and TG11-T5 variants Two polymorphic tracts are found in front of exon 9, a T(n) tract and TG(n) tract. At the Tn locus, three common alleles may be detected: T5, T7 and T9, and a much rarer T3 [54] (respectively a stretch of 5, 7, 9 and 3 T-residues). A T5 CFTR allele can be associated with TG11, TG12, TG13, and, exceptionally, TG15 (respectively 11, 12, 13, and 15 TG repeats) [55] . The number of T and/or TG repeats within these polymorphic tracts affect the extent of correct splicing of exon 9: low numbers of T-residues and high numbers of TG repeats give rise to less efficient splicing [42, 56, 57] . Transcripts that lack exon 9 sequences fail to mature [58, 59] . About 5% of the CFTR genes in the general Caucasian population carry the T5 allele [60] . In most T5 CFTR genes, the number of TG repeats found in cis determines whether the amount of functional CFTR proteins that will be translated does fall above or below the critical level for normal CFTR function [56, 38] . A TG12-T5 or TG13-T5 CFTR gene found in compound heterozygosity with a CF-causing mutation, or possibly even in homozygosity, will in general result in a CFTR-related disorder, such as Congenital Bilateral Absence of the Vas Deferens (CBAVD) or chronic idiopathic pancreatitis. Some CBAVD patients may develop mild lung symptoms. In exceptional cases, TG12-T5 and TG13-T5, may cause a mild form of CF [61] . A TG11-T5 CFTR gene is highly unlikely to cause disease. Approximately 90% of the T5 CFTR genes found in CBAVD patients associate with TG12 or TG13, while about 10% associate with TG11 [56, 38, 62] .
B. R117H-T5 and R117H-T7 complex alleles R117H is a relatively frequent mutation in CF patients worldwide [11] . R117H can be in cis with either T5 or T7 [63] . R117H-T5 will result in less functional CFTR than R117H-T7 [42] . When found in compound heterozygosity with a CFcausing mutation, or possibly even in homozygosity, R117H-T5 generally results in pancreatic sufficient CF, while R117H-T7 may result in a mild form of CF, obstructive azoospermia, or no disease at all.
In newborn screening programs, up to 7% of the newborns who have an elevated immunoreactive trypsinogen test and two mutations are compound heterozygous for R117H-T7 and a CFcausing CFTR mutation [64] . In their first years of life, these children have shown no major signs of CF, although it cannot be excluded that they may develop manifestations of CF disease in adulthood [65] .
C. I148T-3199del6 complex alleles
Soon after the identification of the CFTR gene, the detection of mutations was time-consuming and expensive. If a missense mutation which involved a highly evolutionarily conserved amino acid, and which was not found in a set of control individuals, was identified in a CF patient, it was defined as a CFcausing mutation. In most instances, such a CFTR allele was then not further investigated, since the underlying mutation was assumed to have been identified. Besides, there was a general consensus that only a limited number of mutations would be found in CF patients.
On these grounds, the I148T sequence variation [66] was initially classified as a frequent CF-causing CFTR mutation. The American College of Medical Genetics (ACMG) therefore included the I148T mutation in its mutation panel of 25 mutations that were recommended to be screened in CF carrier testing [67] . Since then, however, it has been found that I148T is a neutral polymorphism [68] [69] [70] . A second mutation, 3199del6 is the underlying mutation in cis in most I148T CFTR genes of CF patients. Since only 1% of all I148T CFTR genes in the general Caucasian population carry the 3199del6 mutation, I148T should not be routinely screened for. In 2004, ACMG recommended to remove I148T from the mutation panel [17] .
Conclusion: A TG13-T5 or TG12-T5 CFTR gene found in compound heterozygosity with a CFcausing mutation may result in CFTR-related disease, or even in a mild form of CF. ATG11-T5 CFTR gene is highly unlikely to cause disease.
When R117H is detected, the T5 or T7 status should also be established. In compound heterozygosity with a CF-causing mutation, or in homozygosity, R117H-T5 generally results in pancreatic sufficient CF, while R117H-T7 may result in a mild form of CF, CBAVD, or no disease at all.
I148T alone is a neutral polymorphism and does not cause CF disease.
Non-CFTR genes causing CF-like clinical syndrome
Not in every patient with CF can a mutation be identified on both CFTR genes. This happens in 1-1.5% of the CFTR alleles of patients with fully expressed disease from Northern Europe and in an even higher proportion of CFTR alleles from Southern Europe [11] . As mentioned before, the inability to detect these mutations may be partially explained by the fact that the currently most advanced CFTR genetic tests study only the coding region and the adjacent exon/intron junctions. Mutations located in the intronic and promoter regions as well as distant regulatory sequences are not routinely screened for, and may therefore be missed.
However, there is emerging evidence that genes other than CFTR may cause a disease clinically indistinguishable from CF. In a German family, no mutation could be identified in both CFTR genes of a CF patient, and his sister, who had inherited the same CFTR genes from their parents, was not affected [71] . In two American families, each of them having two affected sibs, no mutations could be found on both CFTR genes, while both sibs did not inherit the same parental CFTR genes [25] .
CF is characterized not only by defective chloride secretion, but also by increased sodium absorption in the airways. Sodium transport is mediated through the amiloride sensitive epithelial sodium channel, ENaC, which is made of the 3 subunits SCNN1A, SCNN1B and SCNN1G. Over expression of SCNN1B results in increased airway epithelial sodium absorption and CF-like lung disease in mice [72] . There is evidence that mutations in SCNN1B may cause CF-like disease in a small fraction (about 10%) of CF patients in whom a CFTR mutation cannot be found on both CFTR genes [73] . The genetic factor(s) causing CF-like disease in the other patients remains unknown.
Conclusion: There is some evidence that other genes may cause CF-like disease in a small fraction of patients. These findings are too preliminary to be used in a clinical context.
Genetic analysis for outcome prediction
CF is characterized by a wide range of clinical expression. If not detected by neonatal screening, patients are diagnosed with various modes of presentation, involving a variety of CF-affected organs, at different ages, from birth to adulthood. In addition, there is considerable variability in the severity and rate of disease progression of the involved organs. Although the majority of CF patients are diagnosed in the first year of life with signs and symptoms of malnutrition, pancreatic insufficiency (PI) or typical lung disease, an increasing number of patients have been diagnosed in adolescence or adulthood.
The heterogeneous range of phenotypes can be attributed to various factors, such as CFTR genotype, modifier genes and environmental factors, including the beneficial and harmful effects of treatment [74] . The beneficial contribution of therapy is exemplified by the progressive improvement in survival of CF patients over the last 5 decades, which can be attributed entirely to changes in approach to therapy of patients, including provision of pancreatic enzymes, intensive nutritional support, and antibiotics for pulmonary infections, aggressive physiotherapy and multidisciplinary care [75] . Although these environmental modifiers have had a profound effect upon the survival of CF patients as a whole, considerable variation in outcome continues to exist among individual patients, even among those with the same CFTR genotype receiving similar levels of care.
There is substantial interest in the influence of the CFTR genotype on phenotype. The relative impact of CFTR genotype on clinical phenotype is organ specific, with the vas deferens being most sensitive to a small reduction in CFTR function and the lung less influenced [76] . The initial studies of genotype and phenotype relationships focused on patients carrying F508del. Patients homozygous for F508del usually have more pronounced clinical manifestations compared to compound heterozygotes and genotypes without F508del [77] [78] [79] [80] , although these differences are highly variable [77, 81, 82] . Patients homozygous for the F508del mutation have an earlier diagnosis of disease, higher sweat Cl − levels, younger current age and are more likely to be pancreatic insufficient.
In order to collect adequate numbers of patients for comparative analyses, genotype-phenotype correlations have been undertaken using the CFTR mutations classification of five classes, which is shown in Table 5 [83] [84] [85] . In general, patients homozygous for class I-III mutations exhibit a phenotype associated with pancreatic insufficiency, higher frequency of meconium ileus, premature mortality, earlier and more severe deterioration of lung function, higher incidence of malnutrition and severe liver disease. Class IV-V mutations are usually associated with milder lung disease, older age at death, pancreatic sufficiency [77, 86, 44] . Class IV-V mutations are phenotypically dominant when occurring in combination with class I-III mutations. As discussed in more detail below, these differences are not fully explained by clinical measures of lung function, nutrition, and pancreatic insufficiency, suggesting that the CFTR genotype is an independent predictor of survival.
These broad genotype/phenotype associations are useful in epidemiological studies which relate the severity of CF to the class of mutations. While this functional classification of CFTR mutations is widely used in the scientific literature to establish statistical associations, it was not developed as a clinical tool for individual prognostic predictions. Since there is considerable variability in phenotype, even with patients carrying the same genotype, the use of genotype to make statements of prognosis is not recommended. First, the number of mutations so far identified in the CFTR gene is exceedingly high, and most of them are too rare to draw statistical conclusions regarding phenotype. Second, only a fraction of them have been characterized according to their functional consequences. Third, a number of CFTR mutations have several functional consequences, and cannot be assigned to one particular class. Finally, patients homozygous for mutations, like F508del, classically associated with a severe and complete form of CF, exhibit an extremely wide range of severity of pulmonary disease mild disease. Such clinical variability is likely to be even more pronounced by clustering together different mutations belonging to the same class.
Conclusion:
The CF phenotype is affected by the CFTR genotype as well as by other genetic and environmental factors. When patients who are homozygous, or compound heterozygous for a class I-III CFTR mutation, are compared to patients who carry at least one class IV-V CFTR mutation, the latter group tends to have less severe disease. The categorization of CFTR mutations in five classes is a research tool, and is not predictive of clinical outcome in individual patients. Thus, CFTR genotype/phenotype correlations may be useful at a population level to determine associations, but should not be used to indicate prognosis in individual patients.
CF genotype and pancreatic status
Pancreatic insufficiency (PI) and sufficiency (PS) are clinical terms describing the degree of pancreatic function and are Residual expression and function determined by measurement of fat absorption. Pancreatic insufficiency occurs when less than 2% of the exocrine pancreas is functioning, which gives rise to fat malabsorption, thereby requiring exogenous pancreatic enzyme replacement therapy. Pancreatic sufficiency means that the residual exocrine pancreatic function is sufficiently preserved to allow normal fat absorption and therefore enzyme replacement is not required. Pancreatic status is measured by fecal fat, fecal elastase, serum trypsinogen, or quantitative studies of the pancreas. The presence of clinical symptoms suggestive of malabsorption is not an accurate way to determine pancreatic status [87] .
There is a strong relationship between CF genotype and pancreatic status: Class I-III mutations (also called "severe" mutations) are associated with pancreatic insufficiency, and Class IV and V mutations (also called "mild" mutations) with pancreatic sufficiency. A class I-III allele, if paired with another class I-III allele, is associated with PI but the presence of one class IV or V allele is usually enough to confer PS [88] .
These correlations are not absolute, and some mutations may be associated with either pancreatic sufficiency or insufficiency. Patients identified by neonatal screening and who carry class I-III mutations on both alleles may be pancreatic sufficient at diagnosis, but develop PI within the first 1-2years of life [89] . Later in life, although most patients appear to maintain PS for many decades, a small percentage of patients with pancreatic sufficiency appear to develop insufficient digestive function as they grow older. Recurrent acute pancreatitis or chronic pancreatitis is seen in 20% of PS patients, and PI can result from the repeated inflammatory parenchymal damage [90] . Table 6 lists the pancreatic status associated with the most frequent CFTR mutations.
Conclusion:
Patients who carry class I-III mutations on both alleles are likely to be pancreatic insufficient, whereas those carrying at least one class IV-V CFTR mutation has a high probability of being pancreas sufficient. Pancreatic sufficient patients tend to have better nutritional status, but are also at significant risk for developing pancreatitis.
CF genotype and pulmonary involvement
The lung has the greatest variability of disease severity of all organs involved in CF. Modifier genes, environmental and treatment factors all play important roles [78, 80, 82, 88, 79, 81, [91] [92] [93] [94] . CF twin and siblings studies show that the proportion of CF variance that can be attributed to genetic factors, i.e. the heritability, ranges from 0.6 to 0.8 [95, 96] . This indicates that modifier genes are primarily responsible for variation in pulmonary disease severity in patients living in the same household.
Pulmonary phenotype of CF can be determined by pulmonary function tests (e.g. FEV 1 ), bacteriological markers (e.g. age at first acquisition of Pseudomonas aeruginosa, pulmonary exacerbations requiring IVantibiotics), measurement of structural changes (e.g. High Resolution Computed Tomography scores), and by survival. Since CF lung disease is progressive change over time must be taken into account. Large studies have shown that patients with Class I, II and III mutations have a steeper rate of decline in FEV 1 than patients who carry one Class IV or V mutation [97] . However, the variance in FEV 1 in patients within these two groups is considerable and thus prediction of progression of lung disease in individual patients is not possible [82] . A patient who is homozygous or compound heterozygous for class I-III CFTR mutations may present with mild lung disease. On the other hand, patients who carry at least one class IV-V mutations may present with severe disease later in life. Thus, for individual patients, it is impossible to predict reliably the severity of pulmonary disease based only on CFTR genotype. Table 6 Main CFTR mutations as related to pancreatic status Usually PI associated mutations Usually PS associated mutations
PS/PI classification is based on an apparent consensus from literature or from unpublished reports. ⁎may also be associated with PS. ⁎⁎may also be associated with PI.
Conclusion: Since the CFTR genotype is not a useful predictor of the severity of lung disease in the individual patient, it should not be used as an indicator of prognosis.
CF mutations and other disease manifestations
Other manifestations of CF include gastrointestinal complications, CF related diabetes, and male infertility. a. Gastrointestinal complications of CF.
These are mainly meconium ileus (MI), distal intestinal obstruction syndrome (DIOS), and CF liver disease. Genotypephenotype studies of these CF complications are hampered by small sample sizes, as these complications are seen in 5-20% of CF patients, and by difficulty in determining a common definition. This is especially true for CF liver disease, which is insidious in onset, and with no commonly agreed diagnostic criteria. Nevertheless, liver disease, MI and DIOS, occur almost exclusively in patients carrying severe class I-III mutations on both alleles. However, there is no evidence of a phenotype relationship with specific gene mutations [98, 99] . Modifier genes seem to play a prominent role in development of MI [100] and CF-associated liver disease [101] .
b. Diabetes
The prevalence of CF-related diabetes (CFRD) increases with patient age with an overall prevalence of~5%. Around 15-20% of CF adults have CFRD, almost exclusively PI patients, and thus diabetes is strongly associated with Class I, II and III mutations [98, 102] .
c. Male infertility
Obstructive azoospermia is present in the greatest majority of male patients with CF [103, 104] , mainly because of congenital bilateral absence of the vas deferens (CBAVD), but also following other obstructive anatomic abnormalities [105] . CFTR is very important in the normal development of the vas deferens, as relatively minor disruption of CFTR function appears to cause CBAVD. Fertile CF men often carry the 3849 + 10kbC N T mutation. This correlation is very strong and does allow prediction of infertility in men with CF who carry mutations other than 3849+10kbCNT.
Conclusion: There is no correlation between any specific CFTR mutation and meconium ileus, DIOS, liver disease, and CF related diabetes. These manifestations almost never occur in the presence of a PS mutation.
CFTR mutations in the context of CFTR-related disorders
The best studied CFTR-related disorders are CBAVD and other forms of obstructive azoospermia, recurrent acute or chronic pancreatitis, and diffuse bronchiectasis [106] [107] [108] . A prevalence of CFTR mutations higher than expected in the general population has been reported also in rhinosinusitis, allergic bronchopulmonary aspergillosis, and sclerosing cholangitis [44, [109] [110] [111] [112] .
To assess the association between CFTR mutations and these disorders is often difficult. The prevalence of CFTR mutations depends on the number of mutations tested (e.g. a limited panel or full gene sequencing) and on patients' selection criteria. Besides, these clinical entities may have other non CFTR etiologies.
a. Congenital bilateral absence of the vas deferens
Obstructive azoospermia, in which CBAVD is the most common phenotype, is an important cause of infertility and accounts for 1-5% of male infertility. The molecular basis of this condition has been investigated by several groups worldwide with common findings [39, 106, 107, [113] [114] [115] 116, 117] . Shortly after the discovery of the CFTR gene, Dumur et al. showed that a large proportion of sterile men with CBAVD carried F508del [106] . Later studies determined that 80-90% of men with CBAVD carry at least one and 50-60% have two CFTR mutations (including the T5 variant). For those men with 2 CFTR mutations, usually one is CF-causing, and the other is a CFTR-related disorder associated mutation. The F508del mutation is found in 40% of CBAVD patients, followed by the T5 variant in about 35% [39, 62, 107, 115, 116, 118, 119] . R117H was also frequently reported (about 30%) in these patients [107] , usually in association with the T7 variant [63] .
b. Pancreatitis
The evidence of an association of CFTR mutations with CBAVD led Sharer and Cohn to evaluate the possible role of CFTR in chronic pancreatitis and to show that the frequency of a single mutation was 11 fold greater than the expected frequency in a control population [113, 114] . These data were confirmed later by different groups with a frequency of about 30% of chronic pancreatitis patients carrying one CFTR mutation and 10-15% being compound heterozygotes [120] [121] [122] [123] [124] . F508del was the most common severe mutation with the T5 variant, R117H-T7, L206W, D1152H, R1070Q, R347H, R334W, and 2789+5GNA also seen.
c. Bronchiectasis
CFTR mutations were found in 10-50% of series of patients with idiopathic bronchiectasis [108, [125] [126] [127] [128] [129] [130] This variability may be due to the more heterogeneous nature of bronchiectasis and may depend upon how exhaustive was the search for other etiologies. Although the specific CFTR mutations were similar to those seen in men with CBAVD, fewer patients were found to be compound heterozygotes. If the patient is a compound heterozygote, only one mutation is a CF-causing mutation.
Conclusion: A frequency of CFTR mutations higher than in the general population is found in individuals with clinical presentations that do not fulfill the diagnostic criteria of CF, thus called CFTRrelated disorders. CF-causing mutations can be detected, but not in both CFTR genes.
Modifier genes
Identification of genetic modifiers and determination of their clinical effect on CF is expected to become an integral part of assessing disease prognosis, and in some cases may lead to alternative approaches to therapy. Over 30 studies on CF modifier genes have been published since 1998. Most of these studies ascertained very small populations and have not been replicated. Consequently, there have been a number of diverse and contradictory conclusions. The current strategy to clarify this area is to conduct studies on modifiers in large CF patient or family cohorts, in order to increase statistical power of association analyses for various CF clinical traits and specific covariates.
In spite of some discordance in the most representative studies results [131] [132] [133] [134] [135] , a few genes are well-proven to be CF modifiers (TGFbeta1, MBL2). More research has to be done on these and other putative CF modifiers, and therefore caution has to be exercised in interpreting these results. We do not know yet whether the heritability of CF lung disease variation is due to a few genes having major effects, or many genes with minor effects, or some combination of the two. The present level of knowledge does not allow us to use the results so far achieved in a clinical context. However it is anticipated that advances in this area of CF research will provide a basis for prognostic and therapeutic applications for CF management in the not distant future.
Conclusion:
Modifier candidate gene studies have so far identified alleles of real but apparently minor effect. At present time, it does not seem appropriate to test routinely for modulating mutations/genes, as there is no clear clinical relevance, nor therapeutic implications.
Communication of the analysis results
CFTR mutation analysis is among the most common tests in molecular genetics laboratories. In spite of the frequency of the test, considerable differences exist in the extent of mutation testing. The way in which the clinician interprets the report will have a major impact on the further clinical management of the tested individual and his family. Therefore it is crucial that the results are presented in a clear and unambiguous way. Different entities, including the International Organization for Standardization [136] , the Organization for Economic Co-operation and Development (OECD) [137] , and some scientific societies [138, 139] have drafted guidelines describing the information that should be included in the molecular genetics laboratory report to ensure that clinicians and patients receive adequate and understandable information.
It is important that the information flows from the laboratory to the clinician, and also from the clinician to the molecular genetics laboratory. In fact, depending on the indications for testing, the analysis and the report will have to be adapted as to include information pertaining specifically to the reasons why the test was requested, and what its potential clinical utility is.
From the clinician to the molecular analysis laboratory
The Best Practice Guidelines for Reporting Molecular Testing Results included in the OECD guidelines for Molecular Testing [137] states that "as the utility of a genetic test report is often dependent on the accuracy and adequacy of information provided to the laboratory, a request for genetic testing should include all information necessary for the laboratory to perform appropriate testing and interpret results".
These general guidelines also apply to CF genetic testing. It is very important for the molecular genetic laboratory to obtain information on the ethnicity of the individual to be tested, and clear indications for testing, before proceeding to the analysis. This information will help the molecular genetic laboratory to employ the best possible "targeted" diagnostic protocol. Mutations which are found in CFTR-related disorders, like CBAVD or chronic idiopathic pancreatitis, may be different from those in PI CF. Similarly, some mutations may be rare in the local population, but relatively frequent in other ethnic groups.
The indications for testing can be reduced to confirming a clinically proven CF, investigating a suspicion of CF or of a CFTR-related disorder, and prenatal diagnosis. When testing is requested to investigate the possibility of CF, it may be useful to indicate to the laboratory how strong is the evidence so far collected in favour of CF. Usually, the lower is the mean sweat chloride concentration, the less likely it is to find any mutation in the CFTR gene. However, a single CF-causing mutation found by a standard panel together with CF clinical features are highly correlated with the presence of a second deleterious mutation, detectable by more extensive analysis [140] .
Conclusion: Integration of clinical and molecular findings is of paramount importance.Laboratories should request information about race/ethnicity, family history, and reason for testing.
From the molecular analysis laboratory to the clinician
A complete written report should always conclude the testing [137] . The person tested should also receive either a copy of the original laboratory report, or the report will be included in a more comprehensive report of the genetic counselling session or of the hospitalization.
Test results should be reported using the terminology described above: disease-causing mutations, mutations of uncertain clinical relevance, and mutations of unknown clinical relevance. Polymorphisms or mutations with no clinical relevance may be misinterpreted by the clinician or the patient, and should not be mentioned in the report. A statement to this effect should be placed in every report.
The clinical relevance and the consequences of the molecular findings for the individual, and for his/her family should be explained. The information provided should be clear and concise, as too much information may confuse the exact meaning of the result. Referral to a physician belonging to a CF centre or with experience in the care of CF and/or to a genetic counsellor for additional information as well as for further diagnostic work up may be more appropriate.
Laboratories should provide estimated clinical sensitivity and specificity. Clinical sensitivity is defined as the proportion of individuals who have CF and who also have a positive CF test with two identifiable CF-causing mutations. Currently, most laboratories will merely rely on published reports. For example, the panel of 23 mutations proposed by the ACMG will identify about 88% of carriers in Caucasians. Thus, about 77% (88% × 88%) of Caucasians with CF (or the same proportion of carrier couples) will have a positive test result (two mutations identified). In case one or no mutation is identified in a CF patient, laboratories should comment on the feasibility of 
Comments
Cystic fibrosis is an autosomal recessive disorder and therefore both parents of the affected child should be carriers of the disease. It is thus suggested that the parents' DNA should be tested to establish carrier status and origin of each mutation. Once carrier detection is confirmed, this couple has a 25% risk to have an affected child in each pregnancy. Prenatal diagnosis is therefore feasible in this pregnancy and in every subsequent pregnancy of this couple. Since this is an inherited disease, screening for carrier status of other members of their families may also be offered. The parents of the patient and their families should consult with the referring doctor and a genetic counselor.
Molecular biologist Director
Mutations have been classified according to GenBank Accession Number NM_000492. Nucleotide 1 has been counted as the first nucleotide of transcription leading to nucleotide 133 being the first nucleotide of the translation initiation codon. The method used: INNO-LiPA CFTR19 and 17 + Tn update (reverse dot blot) Mutations screened for: F508del, I507del, G542X, 1717-1G N A, G551D, R553X, R560T, Q552X, W1282X, S1251N, 3905insT, N1303K, CFTRdele2,3, 711 + 1G N T, 3272-26A N G, 1898 + 1G N A, I148T ⁎ , 3199del6, 3120 + 1G N A, 394delTT, G85E, E60X, 621 + 1G N T, R117H, 1078delT, R347P, R334W, 2143delT, 2183AA N G, 2184delA, 711 + 5G N A, R1162X, 3659delC, 3849 + 10kbC N A, A455E, T5, T7, T9 ( ⁎ I148T is a neutral polymorphism and does not cause CF disease) The mutation detection rate is about 90% for the North European Caucasian population and ≤ 70% for South European Caucasians. Page 1/1 further testing. Laboratories should also be able to provide estimated clinical sensitivities for other defined racial/ethnic groups that may be tested. Clinical specificity can be defined as the proportion of negative test results among individuals who do not have CF. Analytical error or variable expressivity of certain mutations can reduce the clinical specificity of the test. Although the clinical expression of most of the commonly tested mutations is known to be highly consistent with a classic CF phenotype, there may be some exceptions. For example, the R117H mutation may produce a quite variable clinical phenotype.
Large intragenic CFTR gene deletions and benign variants can lead to incorrect assignment of homozygosity when a mutation is present at the same site on the second allele.
Parental testing to confirm homozygosity is always recommended.
For neonatal screening results, the report will be made available according to the procedures established regionally or nationally for neonatal screening.
Conclusion:
A standard molecular analysis laboratory report should be provided for all diagnostic analysis for CF. A check-list for a standard molecular analysis laboratory report and an example of a typical report are shown in Tables 7 and 8 .
Mutation nomenclature
Mutation nomenclature needs to be accurate and unambiguous. However, the effort of producing a reliable nomenclature has led, in recent years, to wide disparities in the naming of DNA sequence variants. The traditional mutation nomenclature is currently used in the vast majority of research papers, and in the CFGAC Mutation Database. More recently, a completely different nomenclature has been recommended by the Human Genome Variation Society (HGVS) (Human Genome Variation Society. Nomenclature for the description of sequence variations) [141] . HGVS is an international body for defining gene variation nomenclature under the umbrella of the Human Genome Organization (HUGO) and the International Federation of Human Genetics Societies (IFHGS). HGVS nomenclature is still evolving. The simultaneous use of 'traditional' versus 'HGVS' nomenclature is a potential source of confusion, both in the laboratory and the clinical setting. In this regard, the Cystic Fibrosis European Network has produced the following statement: "It is recommended that the symbol Δ is not used, but F508del and I507del are used instead. At present, we advise using the mutation names of the routinely and widely used CFTR mutation database [4] . If HGVS nomenclature is used, reference should be made to the 'traditional' mutation names, to avoid confusion for the referring clinician. HGVS nomenclature can be included in a footnote, if a laboratory considers it essential." [34] . Presently, the parallel HGVS nomenclature will be incorporated into the CFGAC Mutation Database.
Conclusion: Many frequently observed mutations have historical names which do not comply with the HGVS recommendations. Currently most clinicians are familiar with the historical names. Therefore, at present adoption of the standardised system will inevitable result in confusion. It is recommended that laboratory reports include HGVS nomenclature in addition to the traditional name.
Carrier testing and carrier screening
CF carrier testing is advised in relatives of a person with CF or in the partner of a CF carrier who is planning to have children [142] . Carrier testing of children should be deferred until the child is old enough to make an informed decision about the implications of genetic analysis [143] . In several countries, population carrier testing is also offered to individuals or couples with no family history of CF. For over the counter or direct to consumer testing, pre-test information should be given to the individual being tested and genetic counselling should be made available to him/her to review the exact meaning of the result. In this regard, more information about CF testing should be made available to the general public to prepare them to better understand the relevance and impact of testing. Software programs that teach people about the potential value and limitations of the CF carrier testing may offer some useful insights. Population screening for CF carriers should conform to the same basic quality principles as those which apply for the testing of individuals.
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